Cookie policy

This site uses cookies to improve your user experience. By using this website, you agree that we can place cookies on your device. For further information, please read our Privacy And Cookies Policy

I accept the terms and conditions
Skip Ribbon Commands
Skip to main content

News

 

 

Terumo Acquires CE Marking for Kanshas Drug Coated Balloon Catheter for Lower Extremitieshttps://www.terumo-europe.com/en-emea/news/terumo-acquires-ce-marking-for-kanshas-drug-coated-balloon-catheter-for-lower-extremitiesTerumo Acquires CE Marking for Kanshas Drug Coated Balloon Catheter for Lower ExtremitiesTokyo, Japan19/06/2018 22:00:00<p>Terumo Corporation (TSE: 4543) today announced that it acquired CE marking for the Kanshas™ drug coated balloon (DCB) catheter used in the treatment of lower extremity peripheral arterial disease. With a September launch in Europe, Terumo is expected to be the first Japanese company to launch DCB sales in Europe, and the European launch will be followed with launches in Latin America and Asia, as well. Terumo aims a 10% share of the European DCB market in the future.</p>
New data demonstrate clinical experience with LifePearl microspheres in over 300 hepatocellular carcinoma patientshttps://www.terumo-europe.com/en-emea/news/new-data-demonstrate-clinical-experience-with-lifepearl-microspheres-in-over-300-hepatocellular-carcinoma-patientsNew data demonstrate clinical experience with LifePearl microspheres in over 300 hepatocellular carcinoma patientsLeuven, Belgium18/06/2018 22:00:00<p>​Key publication with real life clinical experience in over 300 patients with Hepatocellular Carcinoma (HCC) treated with Drug-eluting microspheres transarterial chemoembolisation (DEM-TACE) LifePearl<sup>® </sup>microspheres</p>
Terumo to Launch the Ultimaster Tansei Drug Eluting Stent in Europehttps://www.terumo-europe.com/en-emea/news/terumo-to-launch-the-ultimaster-tansei-drug-eluting-stent-in-europeTerumo to Launch the Ultimaster Tansei Drug Eluting Stent in EuropeTokyo, Japan23/05/2018 22:00:00
Terumo receives CE Mark for Ultimaster TANSEI drug-eluting stenthttps://www.terumo-europe.com/en-emea/news/terumo-receives-ce-mark-for-ultimaster-tansei-drug-eluting-stentTerumo receives CE Mark for Ultimaster TANSEI drug-eluting stentLeuven, Belgium22/04/2018 22:00:00<p><font size="3">Granting of ‘Conformité Européenne’ a major milestone as Terumo gears up for global launches of next generation drug-eluting stent (DES) </font></p>
Terumo and Quirem welcome the positive reimbursement decision for QuiremSpheres® in the Netherlandshttps://www.terumo-europe.com/en-emea/news/terumo-and-quirem-welcome-the-positive-reimbursement-decision-for-quiremspheres®-in-the-netherlandsTerumo and Quirem welcome the positive reimbursement decision for QuiremSpheres® in the NetherlandsLeuven, Belgium11/04/2018 22:00:00<p style="text-align:justify;">​Terumo and Quirem welcome an important milestone for QuiremSpheres® in the Netherlands and in Europe. QuiremSpheres® is now reimbursed for liver-dominant, non-resectable, colorectal liver metastases in the salvage setting<sup>1</sup>, as concluded by the Dutch National Healthcare Institute ('Zorginstituut'). The treatment consists of the injection of holmium-microspheres in the main liver artery with the purpose of destroying the cancer cells and is referred to as radioembolization or selective internal radiation therapy (SIRT). The National Healthcare Institute concludes that this innovative treatment with holmium-166 microspheres, which has been developed in the Netherlands, meets "established medical science and medical practice"<sup>2</sup> for this indication.</p>